These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 8926500)

  • 21. Effect of Botulinum Toxin A Treatment on Eyelid Pressure in Eyes with Blepharospasm.
    Namiguchi K; Mizoue S; Ohta K; Shiraishi A
    Curr Eye Res; 2018 Jul; 43(7):896-901. PubMed ID: 29641935
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Auditory startle reaction in primary blepharospasm.
    Müller J; Rinnerthaler M; Poewe W; Kofler M
    Mov Disord; 2007 Jan; 22(2):268-72. PubMed ID: 17149731
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Botulinum toxin treatment of synkinesia and hyperlacrimation after facial palsy.
    Boroojerdi B; Ferbert A; Schwarz M; Herath H; Noth J
    J Neurol Neurosurg Psychiatry; 1998 Jul; 65(1):111-4. PubMed ID: 9667571
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Botulinum toxin a in the treatment of blepharospasm: a 10-year experience.
    Silveira-Moriyama L; Gonçalves LR; Chien HF; Barbosa ER
    Arq Neuropsiquiatr; 2005 Jun; 63(2A):221-4. PubMed ID: 16100966
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Botulinum toxin improves lid opening delays in blepharospasm-associated apraxia of lid opening.
    Forget R; Tozlovanu V; Iancu A; Boghen D
    Neurology; 2002 Jun; 58(12):1843-6. PubMed ID: 12084888
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The blink reflex recovery cycle differs between essential and presumed psychogenic blepharospasm.
    Schwingenschuh P; Katschnig P; Edwards MJ; Teo JT; Korlipara LV; Rothwell JC; Bhatia KP
    Neurology; 2011 Feb; 76(7):610-4. PubMed ID: 21321334
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lack of effect of botulinum toxin on cortical excitability in patients with cranial dystonia.
    Allam N; Fonte-Boa PM; Tomaz CA; Brasil-Neto JP
    Clin Neuropharmacol; 2005; 28(1):1-5. PubMed ID: 15711431
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Difference in response to botulinum toxin type A treatment between patients with benign essential blepharospasm and hemifacial spasm.
    Cannon PS; MacKenzie KR; Cook AE; Leatherbarrow B
    Clin Exp Ophthalmol; 2010 Oct; 38(7):688-91. PubMed ID: 20456439
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Orbicularis oculi and orbicularis oris reflexes in blepharospasm and torticollis spasmodica during spasm-free intervals.
    Eekhof JL; Aramideh M; Speelman JD; Ongerboer de Visser BW
    Eur Neurol; 2001; 46(2):75-8. PubMed ID: 11528155
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Characteristics of tear abnormalities associated with benign essential blepharospasm and amelioration by means of botulinum toxin type A treatment.
    Hosotani Y; Yokoi N; Okamoto M; Ishikawa H; Komuro A; Kato H; Mimura O; Gomi F
    Jpn J Ophthalmol; 2020 Jan; 64(1):45-53. PubMed ID: 31823132
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Associative stimulation of the supraorbital nerve fails to induce timing-specific plasticity in the human blink reflex.
    Zeuner KE; Knutzen A; Al-Ali A; Hallett M; Deuschl G; Bergmann TO; Siebner HR
    PLoS One; 2010 Oct; 5(10):e13602. PubMed ID: 21049057
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [The central action of botulinum toxin type A assessed by brain auditory and somatosensory evoked potentials].
    Sławek J; Recławowicz D
    Neurol Neurochir Pol; 2004; 38(2):93-9. PubMed ID: 15307601
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of botulinum toxin type a after topical anesthesia.
    Sami MS; Soparkar CN; Patrinely JR; Hollier LM; Hollier LH
    Ophthalmic Plast Reconstr Surg; 2006; 22(6):448-52. PubMed ID: 17117100
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Is increased blinking a form of blepharospasm?
    Conte A; Defazio G; Ferrazzano G; Hallett M; Macerollo A; Fabbrini G; Berardelli A
    Neurology; 2013 Jun; 80(24):2236-41. PubMed ID: 23751916
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The use of botulinum toxin A for treatment of possible essential blepharospasm in a dog.
    Meyer-Lindenberg A; Wohlfarth KM; Switzer EN
    Aust Vet J; 2003 Oct; 81(10):612-4. PubMed ID: 15080472
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Primary blepharospasm: diagnosis and management.
    Defazio G; Livrea P
    Drugs; 2004; 64(3):237-44. PubMed ID: 14871168
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Treatment of focal dystonia with botulinum toxin A].
    Sojer M; Wissel J; Müller J; Poewe W
    Wien Klin Wochenschr; 2001; 113 Suppl 4():6-10. PubMed ID: 15506045
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Botulinum toxin treatment in the facial muscles of humans: evidence of an action in untreated near muscles by peripheral local diffusion.
    Eleopra R; Tugnoli V; Caniatti L; De Grandis D
    Neurology; 1996 Apr; 46(4):1158-60. PubMed ID: 8780112
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Electrophysiological study for comparing the effect of biological activity between type A botulinum toxins in rat gastrocnemius muscle.
    Kim CS; Jang WS; Son IP; Nam SH; Kim YI; Park KY; Kim BJ; Kim MN
    Hum Exp Toxicol; 2013 Sep; 32(9):914-20. PubMed ID: 23475433
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term efficacy and safety of botulinum toxin A injections to treat blepharospasm and hemifacial spasm.
    Ababneh OH; Cetinkaya A; Kulwin DR
    Clin Exp Ophthalmol; 2014 Apr; 42(3):254-61. PubMed ID: 23844601
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.